MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE VS. CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE PHASE 3 SUCCESSOR-2 TRIAL (SIE 2026) - Oct 6, 2026 - Abstract #C100; "Median age was 68 y. Median number of pri- or LOTs was 2; 92.1% of pts were triple-class-exposed, with 85.8% refractory to anti-CD38 mAb and 75.8% to LEN; 37.2% were exposed to pomalidomide and 7.3% to anti-BC- MA tx. Reused with permission. This abstract was accepted and previously presented at the 2026 ASCO Annual Meeting."
P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • IKZF1
|
|
C. Cerchione1; P. G. Richardson2; F. Schjesvold3; C. Fu4; M. A. Hartley-Brown5; C. Gomez5; D. Reece6; G. Mikala7; O. Alkharabsheh8; C. Parrish9; D. White10; H. Quach11; V. Hungria12; A. Mazumder13; M. S. Raab14; A. Oriol15; Z. Zhou16; A. Rocci17; B. Yu16; M. A. Dimopoulos18
|